Chemotherapy related cognitive dysfunction in breast cancer
Conditions
Interventions
Electroacupuncture group:Electroacupuncture
Healthy control group:None
Sponsors
Tumour Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
25 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria of CRCI: 1 25~55 years old, right-handed, premenopausal, newly diagnosed breast cancer patients (stage ? - ?) received standard chemotherapy scheme within half a year after operation after the end of treatment; Neuropsychological assessment of evidence of cognitive impairment; 2 Diagnosed as cognitive impairment according to MCI-R criteria within 6 months after chemotherapy, and classified as mild cognitive impairment, i.e.: Montreal Assessment Scale (MoCA)<26 points, and MMSE score between 21 and 26 points; 3 There is a causal relationship between chemotherapy and cognitive impairment, and other diseases are excluded; 4 At least one cognitive impairment that does not meet the diagnostic criteria for dementia; 5 Expected survival period of more than 1 year; 6 Sign an informed consent form. Inclusion criteria for the healthy control group (HC group): 1 matched with age, gender, and education level of the CRCI group; 2 No chief complaint of cognitive impairment; 3 The total score of the MMSE scale is greater than 27 points, and the overall cognitive function is normal; 4 Head MRI is normal.
Exclusion criteria
Exclusion criteria: 1 Cognitive impairment caused by traumatic brain injury, cerebrovascular diseases (such as Alzheimer's disease, Parkinson's disease, cerebral infarction, multiple sclerosis, etc.), depression, thyroid disease, tumor brain metastasis, drug or alcohol poisoning; 2 Individuals with cognitive impairment and severe primary diseases of the hematopoietic and endocrine systems caused by severe impairment of heart, liver, lung, and kidney functions; Those who take drugs that can affect cognitive function (such as narcotics, sedatives, antidepressants, etc.); 3 Severe language barriers, blurred vision, hearing loss, and other clinically related symptoms that make it difficult to cooperate in completing neuropsychological assessments; 4 Contraindications to MRI examinations such as claustrophobia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| N-Acetyl-L-aspartic acid/Total creatine;myo-inositol/Total creatine;Choline/Total creatine;Whole brain functional network analysis;Functional connectivity analysis;Brain 1H-MRS data analysis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Minimum Mental State Examination score;Montreal Cognitive Assessment Scale rating;Functional assessment of cancer therapy-cognitive function Scale rating;Auditory Language Learning Test - Huashan Edition Scale rating;Interleukin—1ß;Interleukin—18;nuclear factor kappa-B;nucleotide-binding oligomerization domain-like receptor protein 3;pro-cysteinyl aspartate specific proteinase;Cysteine protease-1;T1 structural image;Head MRI; | — |
Countries
China
Contacts
Public ContactMai Wei
Tumour Hospital of Guangxi Medical University
Outcome results
None listed